SUCRALFATE

Post-LOE

sucralfate

Design Pharmaceuticals

ANDAORALSUSPENSION

Approved

Nov 2024

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

4/8 — Partial

SUCRALFATE (sucralfate) by Design Pharmaceuticals is clinical pharmacology sucralfate is only minimally absorbed from the gastrointestinal tract. Approved for the short-term (up to 8 weeks) treatment of active duodenal ulcer. First approved in 2024.

Drug data last refreshed 20h ago

$0.0BPart D

Mechanism of Action

CLINICAL PHARMACOLOGY Sucralfate is only minimally absorbed from the gastrointestinal tract. The small amounts of the sulfated disaccharide that are absorbed are excreted primarily in the urine. Although the mechanism of sucralfate's ability to accelerate healing of duodenal ulcers remains to be…

Pharmacologic Class:

Aluminum Complex

Indications (1)

the short-term (up to 8 weeks) treatment of active duodenal ulcer

Worked on SUCRALFATE at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.